Yun Feng

Dr. Yun Feng

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2023 in Annals of Medicine
Verified
Journal Article
Open access
YFYun Feng
Yun Feng
TDTian-Jiao Duan
Tian-Jiao Duan
QHQing Huang
Qing Huang
ZLZhi-Yi Li
Zhi-Yi Li
YLYa-Ping Liu
Ya-Ping Liu
HLHongxia Li
Hongxia Li
The objective of this study is to explore the clinicopathological characteristics of gastric cancer and precancerous conditions in patients with primary gastric lymphoma. We analyzed 474 cases of primary gastric lymphoma, mainly DLBCL and MALT, from three clinical centres retrospectively, and compared the clinicopathological parameters of primary gastric lymphoma patients complicated with gastric cancer, precancerous conditions, or with no complications. A total of 5.1% of the patients with primary gastric lymphoma were diagnosed with gastric cancer, including metachronous gastric adenocarcinoma (3.2%) and synchronous gastric adenocarcinoma (1.9%). Of the patients with gastric lymphoma, 14.6% had precancerous conditions including atrophy (14.6%), intestinal metaplasia (8.9%), and low-grade intraepithelial neoplasia (1.9%). Primary gastric lymphoma patients with an ulcerative type (p = 0.009) and Lugano classification stage IIE + IV (p < 0.001) lymphoma had a higher risk of complicating with gastric cancers or precancerous conditions. The rate of infection of Helicobacter pylori (Hp) was 68.4% in patients with primary gastric lymphoma, which was higher in patients with MALT lymphoma (p < 0.001), Lugano classification stage I + II (p < 0.001), and patients complicated with precancerous conditions and gastric cancer (p < 0.001), especially gastric cancer of the intestinal type (p = 0.04). Gastric cancer (95.8%) and precancerous conditions (91.3%) occurred mostly in Hp-infected primary gastric lymphoma patients, with a minor subset of Hp-eradicated patients. Primary gastric lymphoma patients had a higher detection rate of early gastric cancer (25.0%) and a five-year survival rate (40.0%) than the general Chinese population. Patients with primary gastric lymphoma have a high risk of developing gastric cancer and precancerous conditions, and this risk may be related to Helicobacter pylori infection. Follow-up of primary gastric lymphoma provides an opportunity for the detection of early gastric cancer. Key messages 5.1% of the patients with primary gastric lymphoma were diagnosed with gastric cancer. 14.6% of the patients with gastric lymphoma had premalignant lesions including atrophy (14.6%), intestinal metaplasia (8.9%), and low-grade intraepithelial neoplasia (1.9%). Primary gastric lymphoma patients complicating with gastric cancer had a higher infection rate of Helicobacter pylori (100.0%), a detection rate of early gastric cancer (25.0%) and a five-year survival rate (40.0%) than the general Chinese population.

23 January 2022 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
YFYun Feng
Yun Feng
DZDan Zhang
Dan Zhang
YZYan Zhao
Yan Zhao
TDTianjiao Duan
Tianjiao Duan
HSHuanhuan Sun
Huanhuan Sun
SHShuixiang He
Shuixiang He

1 September 2021 in Surgical Oncology
Verified
Journal Article
Closed access
YFYun Feng
Yun Feng
KYKui Yang
Kui Yang
HSHuan-Huan Sun
Huan-Huan Sun
YLYa-Ping Liu
Ya-Ping Liu
DZDan Zhang
Dan Zhang
HLHongxia Li
Hongxia Li

27 November 2023 in Helicobacter
Verified
Journal Article
Open access
YFYun Feng
Yun Feng
QHQing Huang
Qing Huang
MLMiaosha Luo
Miaosha Luo
JWJia Wei
Jia Wei
TGTiantian Gao
Tiantian Gao
TDTianjiao Duan
Tianjiao Duan
Background: Some gastrointestinal disorders may be associated with Helicobacter pylori infection, which not only affect maternal health, but may also lead to adverse pregnancy outcomes. We aim to explore the association between H. pylori and gastrointestinal disorders in pregnant women.Materials and Methods: In total, 503 patients were retrospectively analyzed and divided into the H. pylori‐uninfected group, the H. pylori‐infected group, or the H. pylori‐eradicated group. We analyzed the influence of H. pylori on gastrointestinal diseases during pregnancy among the groups, as well as the severity, symptoms, laboratory tests of the H. pylori‐related diseases.Results: Pregnant women with H. pylori infection had higher risk of nausea and vomiting of pregnancy (NVP) (p < 0.001), severe NVP(p = 0.012), hyperemesis gravidarum (p = 0.027), hematemesis (p = 0.018), hyponatremia (p = 0.033), as well as functional dyspepsia symptoms including epigastric pain (p = 0.004), bloating (p = 0.024), and feeling full quickly in a meal (p = 0.031) compared with those without H. pylori infection. While the prevalence of NVP (p = 0.024), severe NVP (p = 0.009), epigastric pain (p = 0.037), and bloating (p = 0.032) were lower in H. pylori‐eradicated pregnant women than in H. pylori‐infected women. In addition, pregnant women with H. pylori infection had higher risk of spontaneous preterm birth than whom without H. pylori infection (p = 0.033).Conclusions: Helicobacter pylori infection was associated with higher risks of NVP, severe NVP, hyperemesis gravidarum, functional dyspepsia, and spontaneous preterm birth in pregnant women.

1 November 2022 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
YFYun Feng
Yun Feng
DZDan Zhang
Dan Zhang
GHGaixia He
Gaixia He
YLYaping Liu
Yaping Liu
YZYan Zhao
Yan Zhao
SHShuixiang He
Shuixiang He
Background: This study is part of a larger research effort to explore the molecular mechanism of hepatocellular carcinoma, reduce drug resistance and seek new targets. Objective: The objective of this study is to investigate the effect and mechanism of fibroblast growth factor receptor inhibitor AZD4547 on Sorafenib-resistant hepatoma cells. Methods: First, we constructed a Sorafenib-resistant hepatoma cell line Huh7R. Different groups of Huh7R cells were treated with Sorafenib, AZD4547, Sorafenib combined with AZD4547, and normal saline. The cell viability was detected by Cell Counting Kit-8. Then Fibroblast growth factor receptor and Toll-like receptor 4 were detected by Western blot, as well as the LC3 II/I, Beclin1, and P62. In addition, we used the autophagy inhibitor 3-methyladenine to identify the mechanism of AZD4547 combined with Sorafenib for inducing Sorafenib-resistant hepatoma cell death. Results: We find that AZD4547 combined with Sorafenib significantly inhibited the viability of Sorafenib-resistant hepatoma cell Huh7R. As for its mechanism, AZD4547 was able to inhibit fibroblast growth factor receptor activity, promote autophagy and regulate immunity. AZD4547 increased LC3 II/I, Beclin1, and Toll-like receptor 4 proteins, and decreased P62 protein level in Huh7R cells significantly when given in combination with sorafenib. Furthermore, 3-methyladenine inhibited autophagy and reversed the killing effect of the combination of AZD4547 and Sorafenib on Huh7R cells. Conclusion: The inhibition of fibroblast growth factor receptor activity by AZD4547 can significantly enhance autophagy and immune response, as well as promote the death of Sorafenib-resistant hepatoma cells.

23 September 2026 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
QWQiwei Wang
Qiwei Wang
TDTianjiao Duan
Tianjiao Duan
JFJuju Feng
Juju Feng
LSLinqing Sun
Linqing Sun
JWJia Wei
Jia Wei
YFYun Feng
Yun Feng
Helicobacter pylori ( H. pylori ) infection is a well-established risk factor for gastric cancer (GC), acting in part through modulation of the immune checkpoint molecule programmed death-ligand 1 (PD-L1) within the tumor microenvironment (TME). Previous reviews have described H. pylori -induced PD-L1 upregulation, but a synthesis of the underlying molecular regulatory networks—particularly the crosstalk among nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 1 (STAT1), and Sonic Hedgehog (Shh) pathways—is lacking. This review integrates recent basic and clinical findings to elucidate how H. pylori virulence factors, including cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA), orchestrate PD-L1 expression through multiple signaling cascades. We compare the differential effects of distinct virulent strains on PD-L1 upregulation and examine the dual-edged nature of H. pylori -induced PD-L1 overexpression—serving both as a marker of immune suppression and a potential predictor of immune checkpoint inhibitors (ICIs) sensitivity—with emphasis on how Epstein-Barr virus (EBV) infection and microsatellite instability (MSI) modify and amplify this duality. By providing a comprehensive overview of these multi-pathway regulatory mechanisms and their clinical implications, this review aims to offer theoretical foundations and translational guidance for optimizing immunotherapeutic strategies, particularly ICIs, in GC management.